Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis
2021-005288-31Phase 2Active
- Sponsor
- Morphic Therapeutic
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LY4268989 in autoimmune colitis, sponsored by Morphic Therapeutic. Primary endpoint: Change from baseline to Week 12 in Robarts Histopathology Index (RHI) Score. Started May 2022; status: active.
02
Drugs
LY4268989
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2021-005288-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005288-31.